South Africa’s medical aid market is under fresh scrutiny for a pattern that clinicians and members know too well. This has prompted renewed discussion about value-based healthcare and its potential to improve patient outcomes and system sustainability. Schemes routinely fund high-cost, late-stage interventions. Yet they often resist paying for prevention and side-effect management that could avoid hospital admissions later. This…